Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy
JRL Schwartz, NT Feldman, RK Bogan… - Clinical …, 2003 - journals.lww.com
In a multicenter, randomized, double-blind study the authors compared the efficacy of
modafinil 400 mg once daily, 400 mg given in a split dose, or 200 mg once daily for …
modafinil 400 mg once daily, 400 mg given in a split dose, or 200 mg once daily for …
Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis
JL Chapman, A Vakulin, J Hedner… - European …, 2016 - Eur Respiratory Soc
Modafinil is used internationally to treat residual sleepiness despite continuous positive
airway pressure in obstructive sleep apnoea (res-OSA). In 2011, the European Medicines …
airway pressure in obstructive sleep apnoea (res-OSA). In 2011, the European Medicines …
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy
JR Harsh, R Hayduk, R Rosenberg… - … medical research and …, 2006 - Taylor & Francis
Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life
enantiomer of modafinil, for the treatment of excessive sleepiness in patients with …
enantiomer of modafinil, for the treatment of excessive sleepiness in patients with …
Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion
I Arnulf, R Thomas, A Roy, Y Dauvilliers - Sleep Medicine Reviews, 2023 - Elsevier
Idiopathic hypersomnia is a central hypersomnolence disorder of unknown origin
characterized by excessive daytime sleepiness despite normal or long sleep time, and …
characterized by excessive daytime sleepiness despite normal or long sleep time, and …
Treatment of narcolepsy and other hypersomnias of central origin
An American Academy of Sleep Medicine Review… - Sleep, 2007 - academic.oup.com
Objective: The purpose of this paper is to summarize current knowledge about treatment of
narcolepsy and other hypersomnias of central origin. Methods: The task force performed a …
narcolepsy and other hypersomnias of central origin. Methods: The task force performed a …
[HTML][HTML] Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study
PJ Strollo Jr, J Hedner, N Collop, DG Lorch Jr, D Chen… - Chest, 2019 - Elsevier
Background Excessive sleepiness (ES) is a common symptom of OSA, which often persists
despite primary OSA therapy. This phase III randomized withdrawal trial evaluated …
despite primary OSA therapy. This phase III randomized withdrawal trial evaluated …
Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double‐blind, placebo‐controlled study
G Mayer, H Benes, P Young, M Bitterlich… - Journal of sleep …, 2015 - Wiley Online Library
Summary In 2010 the European Medicines Agency withdrew the indication of modafinil for
the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic …
the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic …
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
MJ Thorpy, C Shapiro, G Mayer, BC Corser… - Annals of …, 2019 - Wiley Online Library
Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake
inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the …
inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the …
Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome
JE Black, M Hirshkowitz - Sleep, 2005 - academic.oup.com
Abstract Study Objectives: Nasal continuous positive airway pressure (nCPAP) usually
reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However …
reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However …
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis
P Sheng, L Hou, X Wang, X Wang, C Huang, M Yu… - PloS one, 2013 - journals.plos.org
Background Modafinil is a novel wake-promoting agent approved by the FDA ameliorating
excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder …
excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder …